Global AFP Testing Market Size By Type (Liver Cancer, Testes Cancer), By Application (Hospitals and Clinics, Others), By Region, And Segment Forecasts, 2023 to 2032

lobal AFP Testing Market Report Description

The Global AFP Testing Market was valued at USD 750 million in 2023 and is projected to surpass USD 1.25 billion by 2031, registering a CAGR of 6.7% during the forecast period (2023–2031). Alpha-fetoprotein (AFP) testing plays a critical role in the early detection and monitoring of liver cancer, germ cell tumors, and fetal abnormalities during pregnancy. The market growth is primarily driven by the rising incidence of liver diseases, increasing awareness regarding prenatal screening, and advancements in diagnostic technologies.

The adoption of AFP tests is expanding due to the growing demand for non-invasive, cost-effective, and accurate biomarkers for cancer diagnostics and prenatal screening. Furthermore, the expansion of diagnostic laboratories, rising healthcare expenditure, and integration of automated immunoassay systems are fueling market growth.

Drivers

Rising Prevalence of Liver Cancer and Chronic Liver Diseases

With the increasing incidence of hepatocellular carcinoma (HCC) and cirrhosis, AFP testing is widely used as a biomarker for screening and monitoring treatment outcomes, driving significant demand globally.

Growing Awareness of Prenatal Screening

AFP testing is a crucial prenatal screening tool for detecting neural tube defects (NTDs) and chromosomal abnormalities like Down syndrome. Increasing awareness among expecting mothers and healthcare providers is boosting test adoption.

Technological Advancements in Immunoassay Platforms

Automated and high-throughput immunoassay analyzers with enhanced sensitivity and specificity are improving test accuracy, driving their adoption in hospitals and diagnostic centers.

Restraints

Limited Specificity in Cancer Detection

AFP levels can be elevated in benign liver conditions and during pregnancy, which sometimes leads to false positives and limits its diagnostic accuracy for certain cancers.

High Cost of Advanced Diagnostic Platforms

While basic AFP tests are affordable, advanced immunoassay systems and molecular diagnostic methods are expensive, restricting their adoption in low-resource settings.

Opportunities

Rising Demand in Emerging Markets

Growing healthcare infrastructure and improving access to prenatal care and cancer diagnostics in Asia-Pacific and Latin America create lucrative growth opportunities for AFP test providers.

Integration with Multiplex Biomarker Testing

Combining AFP testing with other biomarkers such as DCP (Des-gamma carboxyprothrombin) or beta-hCG for improved diagnostic accuracy is emerging as a key opportunity for market players.

Home-based and Point-of-Care Diagnostics

Technological innovations enabling rapid AFP testing kits for home and decentralized healthcare settings present a promising market expansion avenue.

Market by System Type Insights

Immunoassay-based AFP Tests dominated the market in 2023, accounting for the largest share due to their widespread availability, cost-effectiveness, and rapid results.

Molecular diagnostic AFP tests are expected to witness the highest growth during the forecast period due to their higher specificity and integration with genetic testing.

Market by End-use Insights

Hospitals and Clinics emerged as the largest end-user segment in 2023, driven by the high volume of prenatal and oncology testing performed in these settings.

Diagnostic Laboratories are expected to grow at the fastest rate, supported by the rise of centralized testing facilities and partnerships with healthcare providers for cancer and prenatal screening programs.

Market by Regional Insights

North America held the largest market share in 2023, driven by the high prevalence of liver cancer, strong healthcare infrastructure, and early adoption of advanced diagnostic technologies.

Asia-Pacific is projected to witness the fastest growth, fueled by high liver cancer incidence in China and Japan, growing awareness of prenatal testing, and expanding diagnostic networks.

Europe remains a significant market, with increasing demand for comprehensive maternal health screening programs.

Competitive Scenario

Key players in the Global AFP Testing Market include:

Abbott Laboratories

Roche Diagnostics

Siemens Healthineers

Beckman Coulter (Danaher Corporation)

Thermo Fisher Scientific

Bio-Rad Laboratories

Fujirebio Diagnostics

PerkinElmer Inc.

These companies focus on technological innovations, strategic partnerships, and regional expansion to strengthen their market positions.

Key recent developments include:

2023: Abbott launched a next-generation AFP immunoassay with improved sensitivity for early-stage liver cancer detection.

2024: Roche Diagnostics partnered with leading hospitals in Asia for integrated prenatal screening programs.

2025: Siemens Healthineers introduced an AI-powered diagnostic platform integrating AFP with multiple tumor markers for better clinical decision support.

Scope of Work – Global AFP Testing Market

Key Market Developments

July 2023: Abbott introduced a high-throughput AFP immunoassay for automated lab analyzers, reducing turnaround time significantly.

May 2024: Roche partnered with Asian healthcare providers to expand AFP testing in population-based liver cancer screening programs.

January 2025: Siemens Healthineers launched a new prenatal screening panel integrating AFP with genetic markers for improved fetal anomaly detection.

FAQs

What is the current market size of the Global AFP Testing Market?

The Global AFP Testing Market was valued at USD 750 million in 2023.

What is the major growth driver of the Global AFP Testing Market?

The rising prevalence of liver cancer and increasing awareness of prenatal screening are the key growth drivers.

Which is the largest region during the forecast period in the Global AFP Testing Market?

North America is expected to remain the largest region, while Asia-Pacific will grow fastest.

Which segment accounted for the largest market share in the Global AFP Testing Market?

The Immunoassay-based AFP testing segment held the largest market share in 2023.

Who are the key market players in the Global AFP Testing Market?

Key players include Abbott, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, and Thermo Fisher Scientific.

Would you like me to also create a visually appealing infographic-style summary for this report (e.g., key numbers, drivers, and opportunities) for presentation or marketing use?